Joshi Avni Y, Mullakary Roshini M, Iyer Vivek N
From the Division of Allergic Disease, Mayo Clinic, Rochester, Minnesota; and.
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
Allergy Asthma Proc. 2020 Jul 1;41(4):296-300. doi: 10.2500/aap.2020.41.200044.
Underlying lung disease, especially asthma, has recently been found to be associated with a higher risk of hospitalization with coronavirus disease 2019 (COVID-19) infection. Inhaled corticosteroids (ICS) are the most commonly used controller medications in patients with asthma. It is unclear whether ICS use increases the risk for severe COVID-19 infection. At the current time, asthma organizations are still recommending the continued use of ICS and other asthma medications to minimize the risk of uncontrolled asthma. However, for patients with asthma and who have recovered from COVID-19 infection, the timing of resumption of asthma therapy is equally uncertain. Pulmonary function testing and exhaled oral nitric oxide testing are aerosol-generating procedures and are currently being severely restricted at most health-care facilities. We presented a case of a patient with cough-variant asthma who developed severe COVID-19 associated acute respiratory distress syndrome with the need for intubation and prolonged mechanical ventilation. We highlighted the potential utility of using COVID-19 RNA detection as well as immunoglobulin G antibody testing to help guide the timing of resumption of asthma therapy.
最近发现，潜在的肺部疾病，尤其是哮喘，与2019冠状病毒病（COVID-19）感染导致的更高住院风险相关。吸入性糖皮质激素（ICS）是哮喘患者最常用的控制药物。目前尚不清楚使用ICS是否会增加严重COVID-19感染的风险。目前，哮喘组织仍建议继续使用ICS和其他哮喘药物，以将哮喘失控的风险降至最低。然而，对于已从COVID-19感染中康复的哮喘患者，恢复哮喘治疗的时机同样不确定。肺功能测试和呼出一氧化氮测试是产生气溶胶的操作，目前在大多数医疗机构都受到严格限制。我们报告了一例咳嗽变异性哮喘患者，该患者发展为与COVID-19相关的严重急性呼吸窘迫综合征，需要插管和长时间机械通气。我们强调了使用COVID-19 RNA检测以及免疫球蛋白G抗体检测来帮助指导哮喘治疗恢复时机的潜在作用。
